CPS Technologies (CPSH) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
29 Jan, 2026Executive summary
Q3 2024 revenue declined to $4.2 million, down 32% year-over-year, mainly due to the end of a major U.S. Navy armor contract and reduced orders from a key customer working through excess inventory.
Gross margin dropped to negative 12% from 20% last year, impacted by lower sales, manufacturing inefficiencies, and start-up costs for a new third shift.
Operating loss was $1.5 million versus operating income of $0.1 million in Q3 2023; net loss was $1.0 million, or $0.07 per share, compared to net income of $0.2 million, or $0.01 per share, last year.
SG&A expenses decreased 13% in Q3 2024, reflecting lower variable compensation and payroll.
Management anticipates improved performance in Q4 and fiscal 2025, citing new contract wins and increased production capacity.
Financial highlights
Q3 2024 revenue: $4.2 million, down from $6.3 million in Q3 2023; nine months: $15.2 million, down 27% year-over-year.
Gross loss: $0.5 million, or negative 12% of revenue, versus gross profit of $1.2 million, or 20% of revenue, in Q3 2023.
Cash and cash equivalents at quarter-end were $4.7 million, with $1 million in marketable securities.
Accounts receivable stood at $3.7 million, and inventories at $4.4 million.
Book to bill ratio stands at 1.22, indicating future revenue growth.
Outlook and guidance
Management expects to fund operations for the remainder of 2024 and 2025 from operations and existing cash balances.
Optimism for Q4 and fiscal 2025 due to resumed customer orders, new contracts, and increased manufacturing capacity.
Gross margins expected to improve as volumes increase in Q4 and 2025.
New $12 million semiconductor contract and DOE Phase 2 SBIR award expected to boost future revenue.
Commercialization of fiber-reinforced aluminum (FRA) composites anticipated in 2025.
Latest events from CPS Technologies
- Q2 2026 revenue up to $8.3M, $9.6M raised, and margin recovery amid rising costs.CPSH
Q2 2026 - Q1 2026 revenue and margins declined, but growth and margin recovery are expected ahead.CPSH
Q1 2026 - 2026 meeting seeks approval for directors, executive pay, share increase, and auditor ratification.CPSH
Proxy filing - Annual meeting to vote on directors, executive pay, share increase, and auditor ratification.CPSH
Proxy Filing - Record revenue, margin gains, and facility expansion drive strong growth outlook.CPSH
Q4 2025 - Record revenue, margin gains, and major contracts drive expansion amid ongoing market risks.CPSH
Q3 2025 - Record Q2 2025 revenue, profitability, and strong demand drive a positive outlook.CPSH
Q2 2025 - Revenue and margins fell in Q2, but new contracts and product launches support future growth.CPSH
Q2 2024 - Record Q1 2025 revenue and profitability, with strong growth and improved margins.CPSH
Q1 2025